Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease

BACKGROUND: Atypical hemolytic uremic syndrome is a rare group of disorders that have in common underlying complement amplifying conditions. These conditions can accelerate complement activation that results in a positive feedback cycle. The known triggers for complement activation can be diverse an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Ramy M., Merin, Noah, Burwick, Richard M., Abdelnour, Lama, Selamet, Umut, Yanny, Beshoy, Bui, Patrick, Fouad, Mary, Kurtz, Ira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732828/
https://www.ncbi.nlm.nih.gov/pubmed/31516395
http://dx.doi.org/10.1186/s12959-019-0207-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732828/
https://www.ncbi.nlm.nih.gov/pubmed/31516395
http://dx.doi.org/10.1186/s12959-019-0207-7

Ejemplares similares